文献速递膀胱癌与上尿路尿路上皮癌

上尿路尿路上皮癌的局灶性冲洗样本可识别诊断和预后相关的基因组异常

Diagnostic and prognostic genomic aberrations in upper tract urothelial carcinoma can be identified in focal barbotage samples.
PubMed 文献 · BJU Int · 2024-12-09

这项前瞻性研究对42例输尿管肾镜检查确诊的上尿路尿路上皮癌患者的局灶性冲洗样本进行385基因二代测序,40例成功测序,36例检出已知或疑似致病突变及其他基因组异常,常见TERT(78%)、FGFR3(50%)、KMT2D(42%)、KDM6A(42%)、ARID1A(39%)、TP53(19%)及9q缺失(50%),FGFR3突变见于1、2级肿瘤而不见于3级,TP53变异/缺失及MDM2扩增仅见于高级别或发生转移/死亡的低级别肿瘤患者。

要点

  • 局灶性冲洗样本可行基因测序,40例中36例检出已知或疑似致病突变及其他基因组异常。
  • FGFR3致病突变常见于1、2级肿瘤,3级肿瘤中未见,携带者随访期间无死亡。
  • TP53变异/缺失及MDM2扩增仅见于高级别肿瘤或发生转移/死于尿路癌的低级别肿瘤患者。

核心结论

  • 局灶性冲洗样本可识别基因突变及其他遗传学异常,可能为组织病理学和细胞学增添重要预后信息。
  • 在诊断时对UTUC患者进行更精细的预后判断可指导治疗决策和随访方案。

研究设计与样本

  • 前瞻性研究,纳入42例经输尿管肾镜检查确诊的上尿路尿路上皮癌患者的局灶性冲洗样本。
  • 冲洗标本用于细胞学检查和基因测序,肿瘤分级由细胞学和/或活检或根治性肾输尿管切除术样本确定。
  • 采用385基因面板进行二代测序,识别单核苷酸变异(SNV)、缺失/插入(indel)和拷贝数异常(CNA),并对SNV/indel进行人工过滤以识别可能的致病突变。

主要发现

  • 42例样本中2例质控失败,40例局灶性冲洗样本完成测序。
  • 36例样本中检出已知和疑似致病突变及其他基因组异常。
  • 最常见的变异为TERT(78%)、FGFR3(50%)、KMT2D(42%)、KDM6A(42%)、ARID1A(39%)、TP53(19%)和9q缺失(50%)。
  • FGFR3已知致病突变常见于1级和2级肿瘤,但未见于任何3级肿瘤;携带FGFR3突变的患者随访期间无死亡。
  • TP53变异或缺失以及MDM2扩增仅见于高级别肿瘤或发生转移/死于尿路癌的低级别肿瘤患者;40例冲洗样本中36例检出CNA,高级别样本中占91%,低级别样本中占69%,包括全部5例发生转移或死于尿路癌的低级别肿瘤患者。

局限性

  • 42例样本中2例质控失败,未能完成测序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether genetic analysis of focal barbotage samples obtained at ureterorenoscopy (URS) is possible, and to identify genetic aberrations that might add prognostic information. METHODS: This prospective study included barbotage samples from 42 patients with upper urinary tract urothelial carcinoma (UTUC) confirmed at URS. At URS, focal barbotage specimens were collected for cytology and for gene sequencing. Tumour grades were determined from cytology and/or biopsy, or from radical nephroureterectomy samples. Next-generation sequencing using a 385-gene panel was performed and single nucleotide variants (SNVs), deletions/insertions (indels) and copy number aberrations (CNAs) were identified. Manual filtering of the SNVs/indels was performed to identify possible pathogenic mutations. RESULTS: Of the 42 samples, two failed quality control, therefore, 40 focal barbotage samples were sequenced. We identified known and suspected pathogenic mutations and other genomic aberrations in 36 samples. The most common variants were in TERT (78%), FGFR3 (50%), KMT2D (42%), KDM6A (42%), ARID1A (39%), TP53 (19%) and deletion of 9q (50%). Known pathogenic mutations in FGFR3 were common in grade 1 and 2 tumours, but not present in any grade 3 tumour. No patients with an FGFR3 mutation died during follow-up. TP53 variants or deletions, as well as amplifications of MDM2, were only present in high-grade (HG) tumours or low-grade (LG) tumours in patients who had metastasis/died from urinary tract carcinoma. CNAs were detected in 36/40 barbotage samples, 91% of the HG samples and 69% of the LG samples, including those from all five patients with LG tumours with metastasis or who died from urinary tract cancer. CONCLUSION: Focal barbotage samples enable identification of gene mutations and other genetic aberrations that may add important prognostic information to histopathology and cytology. Refined prognostication of UTUC patients already at diagnosis can guide treatment decisions and follow-up programmes.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Axelsson TA, Sydén F, Eisfeldt J, et al. Diagnostic and prognostic genomic aberrations in upper tract urothelial carcinoma can be identified in focal barbotage samples. BJU Int. 2024. PMID: 39654327. doi:10.1111/bju.16620

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。